{
    "clinical_study": {
        "@rank": "55308", 
        "acronym": "LoGo", 
        "arm_group": [
            {
                "arm_group_label": "Low Dose Gonal-f\u00ae Protocol", 
                "arm_group_type": "Experimental", 
                "description": "Gonal-f\u00ae will be self-administered subcutaneously at a starting dose of 50 International unit (IU) for Week 1, then (if required) dose will be gradually increased by 12.5IU, for two weeks with a final increase of 25IU, up to maximum dose of 100 IU, until Week 4"
            }, 
            {
                "arm_group_label": "Standard Low Dose Gonal-f\u00ae Protocol", 
                "arm_group_type": "Active Comparator", 
                "description": "Gonal-f\u00ae will be self-administered subcutaneously at a starting dose of 50 International Units (IU) for Week 1, then (if required) dose will be gradually increased by 25 IU, every week, up to maximum dose of 125 IU, until Week 4"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a prospective, multicenter, open-label, comparative and parallel-group study of\n      ovulation induction evaluating tailoring of Recombinant follicle stimulating hormone (FSH)\n      treatment using the Gonal-f\u00ae prefilled pen in World Health Organization (WHO) Type 2\n      anovulatory subjects who have previously failed to conceive with clomifene treatment."
        }, 
        "brief_title": "Low-dose Gonal-f\u00ae in Ovulation Induction", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Infertility", 
            "Monofollicular Development"
        ], 
        "condition_browse": {
            "mesh_term": "Infertility"
        }, 
        "detailed_description": {
            "textblock": "Subjects will enter a screening period of up to one month before being randomized at the\n      Baseline Visit, which will occur on Day 1 of the subject's menstrual cycle. Each subject\n      will then receive up to 4 weeks treatment with Gonal-f\u00ae. If adequate follicular development\n      (assessed by transvaginal ultrasound) is achieved, the subject will proceed to\n      administration of  human chorionic gonadotropin (hCG) within 24-48hrs of last Gonal-f\u00ae\n      injection (or according to standard site practice).\n\n      Following administration of hCG, subjects will attempt to become pregnant via intercourse or\n      intrauterine insemination. The method of conception will be determined by the subject's\n      requirements and standard practice at the clinic site.\n\n      All subjects will be followed up appropriately until confirmation of biochemical pregnancy\n      (hCG + minimum 14 days) and clinical pregnancy (hCG + minimum 42 days, for subjects with\n      positive biochemical pregnancy test)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects eligible for ovulation induction treatment, where monofollicular development\n             is the desired treatment outcome and the dose schedule outlined in the protocol is\n             deemed appropriate\n\n          -  Premenopausal female subjects, aged between 18 and 37 years inclusive\n\n          -  Subjects desirous of pregnancy/willing to conceive\n\n          -  Subjects who are infertile due to chronic anovulation demonstrated by cycle duration\n             of greater than 35 days.\n\n          -  Subjects who have been treated with clomifene citrate therapy, according to standard\n             site practice, and have failed to ovulate and/or conceive\n\n          -  Subjects with follicle stimulating hormone (FSH) and prolactin (PRL) serum values\n             within the normal range in the early follicular phase\n\n          -  Subjects with an overall total antral follicle count greater than 10 (of follicle\n             size greater than or equal to 2 millimeter [mm] and less than 11 mm) (that is, total\n             between both ovaries)\n\n          -  Subjects with at least one patent tube, as documented by recent (within 2 years\n             before treatment assignment) hysterosalpingography (HSG) or hysterosalpingo contrast\n             sonography (HyCoSy)\n\n          -  Subjects  with  normal  uterine  cavity,  as  documented  by recent  (within  2\n             years  before  treatment  assignment) hysteroscopy, HSG or ultrasound scan\n\n          -  Subjects  with  body  mass  index  (BMI)  greater than 20  and  less than or equal to\n             32  kilogram per square meter (kg/m^2) (BMI is equal to body weight [kilogram {kg}]\n             divided by Height * Height [square meter {m^2}])\n\n          -  Subjects  with  negative  cervical Papanicolaou  (PAP)  test conducted  according  to\n              national  guidelines  and/or  standard site practice\n\n          -  Male partners of female subjects with sperm compatible with non-assisted\n             fertilization or availability of donor sperm, as confirmed by the Investigator\n\n          -  Subjects who are willing and able to comply with protocol requirements and have\n             provided written, informed consent\n\n        Exclusion Criteria:\n\n          -  Subjects with history of hypersensitivity to the investigational medicinal product\n             (IMP) (active substance follitropin alpha, FSH, or to any of the excipients of\n             Gonal-f\u00ae) or any other drug used in the trial (that is, Ovitrelle)\n\n          -  Subjects with ovarian enlargement or ovarian cyst unrelated to Polycystic Ovary\n             Syndrome (PCOS), and of unknown origin on ultrasound\n\n          -  Subjects with evidence of diminished ovarian reserve (cycle length less than 26 days;\n             FSH above the upper limit of local serum FSH values, total antral follicle count\n             [AFC] in both ovaries less than 10)\n\n          -  Subjects with uterine pathology/abnormalities, which in the opinion of the\n             Investigator could impair pregnancy evolution\n\n          -  Subjects  who  have  undergone  three  or  more  previous miscarriages\n\n          -  Subjects with any previous extrauterine pregnancy\n\n          -  Pregnant or lactating female subjects\n\n          -  Subjects with abnormal gynecological bleeding of unknown etiology.\n\n          -  Subjects  with  previous  history  of  severe  ovarian hyper stimulation syndrome\n             (OHSS)  (after clomifene treatment)\n\n          -  Subjects  who  have  evidence  of  current  or  previous  pelvic inflammatory disease\n             before treatment assignment\n\n          -  Subjects  with  tumors  of  the  hypothalamus  and  pituitary gland\n\n          -  Subjects with ovarian, uterine or mammary carcinoma\n\n          -  Subjects  treated  with  clomifene  citrate  or  gonadotropins within 1 month of the\n             screening evaluation\n\n          -  Subjects with any medical condition which, in the opinion of the  Investigator,\n             would  prevent  an  effective  response,  such as  primary  ovarian  failure,  or\n             malformations  of  the reproductive organs incompatible with pregnancy\n\n          -  Subjects with any medical condition which, in the opinion of the  Investigator,  may\n             interfere  with  the  absorption, distribution, metabolism or excretion of the drug\n\n          -  Subjects with any clinically significant systemic disease (for example,\n             insulin-dependent diabetes) or any contraindication to being pregnant and/or carrying\n             a pregnancy to term\n\n          -  An active substance abuser\n\n          -  Known  infection  with  human  immunodeficiency  virus (HIV), Hepatitis B or C virus\n             in the trial subject or her male partner\n\n          -  Subjects  who  are  currently  participating  in  another  clinical trial\n\n          -  Subjects who are unable to give written informed consent"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "37 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "110", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01871532", 
            "org_study_id": "EMR700623_535", 
            "secondary_id": "2012-003227-38"
        }, 
        "intervention": {
            "arm_group_label": [
                "Low Dose Gonal-f\u00ae Protocol", 
                "Standard Low Dose Gonal-f\u00ae Protocol"
            ], 
            "intervention_name": "Gonal-f\u00ae", 
            "intervention_type": "Drug", 
            "other_name": "Recombinant follicle stimulating hormone (r-FSH)"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Hormones", 
                "Follicle Stimulating Hormone"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Monofollicular Development", 
            "Gonal-f\u00ae", 
            "Recombinant Follicle Stimulating Hormone", 
            "Ovarian hyperstimulation syndrome (OHSS)"
        ], 
        "lastchanged_date": "April 29, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Cork", 
                        "country": "Ireland"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Galway", 
                        "country": "Ireland"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cambridge", 
                        "country": "United Kingdom"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cheshunt", 
                        "country": "United Kingdom"
                    }, 
                    "name": "Research site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Derby", 
                        "country": "United Kingdom"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Edinburgh", 
                        "country": "United Kingdom"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Glasgow", 
                        "country": "United Kingdom"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom"
                    }, 
                    "name": "Research site"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Ireland", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Multi-Centre, Two-Arm, Interventional, Phase IV Study to Evaluate Tailoring of Recombinant FSH Treatment in Subjects With Chronic Anovulation Using the Gonal-f\u00ae Prefilled Pen in Women Undergoing Ovulation Induction", 
        "overall_official": {
            "affiliation": "Merck Serono Limited, UK", 
            "last_name": "Medical Responsible", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "United Kingdom: National Health Service", 
                "United Kingdom: National Institute for Health Research", 
                "United Kingdom: Research Ethics Committee", 
                "Ireland: Irish Medicines Board", 
                "Ireland: Research Ethics Committee"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Percentage of cycles with monofollicular development that is, only one follicle greater than or equal to 17 millimeter and no other follicles greater than or equal to 14 millimeter", 
            "safety_issue": "No", 
            "time_frame": "up to 4 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01871532"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Percentage of cycles with bifollicular development that is, only two follicles greater than or equal to 17 millimeter", 
                "safety_issue": "No", 
                "time_frame": "up to 4 weeks"
            }, 
            {
                "measure": "Percentage of cycles with multifollicular development that is, three or more follicles greater than or equal to 14 millimeter", 
                "safety_issue": "No", 
                "time_frame": "up to 4 weeks"
            }, 
            {
                "measure": "Percentage of ovulatory cycles", 
                "safety_issue": "No", 
                "time_frame": "up to 42 days post human chorionic gonadotrophin (hCG) administration"
            }, 
            {
                "measure": "Percentage of cycles wherein hCG was not administered", 
                "safety_issue": "No", 
                "time_frame": "up to 4 weeks"
            }, 
            {
                "measure": "Percentage of cycles resulting in clinical pregnancy", 
                "safety_issue": "No", 
                "time_frame": "35-42 days post hCG administration"
            }, 
            {
                "measure": "Number of multiple pregnancy", 
                "safety_issue": "No", 
                "time_frame": "35-42 days post hCG administration"
            }, 
            {
                "measure": "Number of fetuses", 
                "safety_issue": "No", 
                "time_frame": "35-42 days post hCG administration"
            }, 
            {
                "measure": "Number of miscarriages after confirmation of clinical pregnancy", 
                "safety_issue": "No", 
                "time_frame": "35-42 days post hCG administration"
            }, 
            {
                "measure": "Number of subjects with Ovarian Hyper Stimulation Syndrome (OHSS)", 
                "safety_issue": "Yes", 
                "time_frame": "up to 42 days post hCG administration"
            }, 
            {
                "measure": "Duration of Recombinant Follicle Stimulating Hormone (rFSH) stimulation", 
                "safety_issue": "No", 
                "time_frame": "up to 4 weeks"
            }, 
            {
                "measure": "Total Dose of Recombinant Follicle Stimulating Hormone (r-FSH) administered per cycle", 
                "safety_issue": "No", 
                "time_frame": "up to 4 weeks"
            }, 
            {
                "measure": "Change from Baseline in Anti-Mullerian Hormone (AMH) levels at Week 4", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 4"
            }, 
            {
                "measure": "Testosterone levels", 
                "safety_issue": "No", 
                "time_frame": "Baseline"
            }, 
            {
                "measure": "Sex Hormone Binding Globulin (SHBG) levels", 
                "safety_issue": "No", 
                "time_frame": "Baseline"
            }
        ], 
        "source": "Merck KGaA", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck KGaA", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}